Silverback Therapeutics

ARS Pharmaceuticals, Inc. engages in developing neffy™, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. The company is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported that Richard Lowenthal, M.Sc., MSEL, co-founder and chief executive officer, and Eric Karas, chief commercial officer, will participate in a fireside chat during the SVB Securities Virtual Global Biopharma Conference 2023 on Thursday, February 16, 2023 at 2:20 p.m. ET.

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

Fintel reports that Tanimoto Sarina has filed a 13D form with the SEC disclosing ownership of 6,265,170 shares of Silverback Therapeutics Inc (SBTX).

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy ® in the U.S., if Approved

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review ARS Pharmaceuticals, Inc.'s (ARS Pharma) New Drug Application (NDA) for neffy for the emergency treatment of allergic reactions (type I) including anaphylaxis in adults and children ≥30 kg (66 lbs).

Silverback Therapeutics, Inc. announces the FDA's acceptance of ARS Pharmaceuticals' NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

SILVERBACK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX

Resolute Forest Products

Terminix Global Holdings

Meridian Bioscience

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Terminix Global Holdings, Inc. (NYSE: TMX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Rentokil Initial plc.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

Hanger Inc

Infrastructure & Energy Alternatives

Zymergen

NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hanger, Inc. (NYSE: HNGR)'s  sale to Patient Square Capital for $18.75 in cash per share. If you are a Hanger shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY

PBF Logistics

Romeo Power

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Silverback Therapeutics, Inc. (NASDAQ: SBTX) 's  merger with ARS Pharmaceuticals, Inc. Under the terms of the merger agreement, assuming that Silverback's net cash at closing is $240 million, Silverback equity holders are expected to own approximately 37% of the combined company. If you are a Silverback shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RMO

NEW ORLEANS , Aug. 10, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

SILVERBACK THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Silverback Therapeutics, Inc. - SBTX

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Silverback Therapeutics, Inc. (NASDAQ: SBTX) 's  merger with ARS Pharmaceuticals, Inc. Under the terms of the merger agreement, assuming that Silverback's net cash at closing is $240 million, Silverback equity holders are expected to own approximately 37% of the combined company. If you are a Silverback shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RFP

Fathom Digital Manufacturing Co

ThermoGenesis Holdings, Inc

View

Penny stocks to watch right now The post Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins

NEW YORK , July 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Silverback Therapeutics, Inc. (SBTX), relating to its proposed merger with ARS Pharmaceuticals, Inc. Under the terms of the agreement, SBTX equity holders are expected to own approximately 37% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/silverback-therapeutics-inc.

Shareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTX

NEW YORK , July 22, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX), in connection with the Company's proposed merger with ARS Pharmaceuticals, Inc. ("ARS").  Under the terms of the merger agreement, assuming that the Company's net cash at closing is $240 million, Silverback equity holders are expected to own only approximately 37% of the combined company and pre-merger ARS equity holders are expected to own approximately 63% of the combined company.

SHAREHOLDER ALERT: Weiss Law Investigates Silverback Therapeutics, Inc.

Wilmington, Delaware--(Newsfile Corp. - July 22, 2022) - Rigrodsky Law, P.A. is investigating Silverback Therapeutics, Inc. ("Silverback") (NASDAQ: SBTX) regarding possible breaches of fiduciary duties and other violations of law related to Silverback's agreement to merge with ARS Pharmaceuticals, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-silverback-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky Law, P.A., with offices in Delaware and...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Silverback Therapeutics, Inc. Merger

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Silverback Therapeutics, Inc. (NASDAQ: SBTX) and ARS Pharmaceuticals, Inc. is fair to Silverback shareholders. Under the terms of the merger agreement, assuming that Silverback's net cash at closing is $240 million, Silverback equity holders are expected to own approximately 37% of the combined company. Halper Sadeh encourages Silverback shareholders to click here to learn more about

SBTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Silverback Therapeutics, Inc. Is Fair to Shareholders

Less than two years after its IPO and months after shutting down its once-promising oncology program, Seattle-based Silverback Therapeutics will merge with another biotech company, San-Diego based ARS Pharmaceuticals.

Silverback Therapeutics to merge with San Diego biotech company developing EpiPen alternative

SEATTLE & SAN DIEGO--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS's investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022. Laura Shawver, Ph.D., Silverback's Chief

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update. “In the first quarter of 2022, we have made significant progress in adva

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continue the advancement of early-stage discovery research.

Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce

Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.

Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today provided an update on strategic priorities and reported financial results for the fourth quarter and full year ended December 31, 2021. “Upon comprehensive review of our clin

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022. Laura Shawver, P

Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference

Array Technologies

AvePoint

Genius Sports

Kronos Bio

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. Laura Shawver, Ph.

News for Silverback Therapeutics Stock (SBTX)